A case study from a patient with Long Haulers who was recommended Tollovid by their physician Dr. Lee Morgentaler.
Post-Acute Sequelae of SARS-CoV-2 (PASC), as known as "Long Haulers", is a major public health problem. Todos Medical reported a Day 28 update from an ongoing case study by Dr. Lee Morgentaler of a 3CL protease cleanse with Tollovid, a 3CL protease inhibitor dietary supplement, in a patient who originally contracted COVID in December 2021 and experienced symptoms of Long COVID, including erectile dysfunction.
SUMMARIZED CASE REPORT:
A 36-year-old, 5’ 8 ½” athletic male with a premorbid weight of 179 pounds, states he was able to overcome a case of Long COVID using an all-natural dietary supplement. The subject is a Canadian government worker. He self describes as having led a very active life which included playing hockey at least 1 time a week, resistance training at least 2 times a week and jogging about 5 kilometers, 3 times a week. He could perform 20 pullups, 100 pushups, and 100 sit-ups during a workout session. On May 24, 2021 he received his first vaccination shot from Pfizer. On July 5, 2021 he received his second vaccination shot from Moderna. There were no immediate side effects noted from either shot.
On December 17, 2021 he tested PCR positive via nasal pharyngeal swab. The suspected source of infection was a co-worker who tested PCR positive on December 14, 2021. Within 3 days of known exposure, the subject manifested symptoms including headache, runny nose, chills, sore throat, and cough. He spent 10 days in isolation with many of the symptoms abating by the 5th day. Of note was a lingering cough which continued for an additional 12 days.
On January 2, 2022 the subject experienced what he perceived as significant personal stress, dealing with the death of his dog. Three days later the subject restarted his workout regimen. After his first workout he experienced pain in his chest and felt uncoordinated. He noticed that he was unable to grasp kitchen cabinets on the first try. The following day it grew in severity, and he couldn’t lift his left arm due to a sensation of “pins and needles.” Approximately 5 days later after he started exercising, he observed changes in his stool noting they appeared as “yellow mush.” The subject described worsening symptoms including extreme fatigue, muscle twitches, frequent urination, loss of libido, sleep disturbance, and anxiety.
On January 26, 2022 the subject was administered a MRNA booster shot. Almost immediately after the booster shot, he felt 90% relief from his extreme fatigue. The pins and needles tingling, GI tract issues, muscle twitches, frequent urination, erectile dysfunction, insomnia, and anxiety were still prevalent. The subject noted his scrotum was red and inflamed and sought treatment with a urologist. There was no significant finding.
Physical activity was very limited as the subject was unable to climb a run of stairs without feeling exhausted from the relatively minor physical exertion. The frequent urination resolved by the end of February 2022. An extensive 49 marker blood panel was drawn on March 9, 2022, that noted markers within normal ranges except for D-Dimer of 912ug/ml and mean cell Hemoglobin of 354g/L, which are both considered high. In mid-April, the doctor prescribed 40mg of fluvoxamine daily for anxiety. The subject noted a reduction in symptoms within 2 weeks of treatment. The subject underwent 4 sessions of HBOT treatment at 2.0 atmospheres following which he experienced one night of solid sleep which he attributed to the HBOT treatments.
On May 11, 2022, the subject started taking a regimen of Tollovid 3 pills 4 times daily for 10 days. On May 13, 2022 the subject reported waking up with an erection. The night of May 13th, 2022 the subject’s stools returned to normal and he was able to nap as desired without anxiety. The visible redness of the scrotum also started to subside. On May 16th, 2022 the subject reported less frequent pins and needles sensation in his left side. The muscle twitching was more localized.
On June 3rd, the subject reported less fatigue, significantly reduced inflammation in the scrotum, normalization of perspiration to pre-COVID state, and reduction in neurological symptoms (primarily pins & needles). The subject reported, “Tollovid has gotten me back to 85% of my pre-COVID state. No other intervention I’ve tried so far has been able to do that.” The subject has agreed to continue to participate in the Case Study series with Tollovid to advance the Company’s understanding of Long COVID. The subject is preparing to perform a follow-up blood panel test to evaluate any changes in previous results in addition to cPass neutralizing antibody testing.
This case study may demonstrate the viral persistence of SARS-CoV-2 in the subject’s scrotum was the proximal cause of the patient’s erectile dysfunction. A major life stressor may have weakened the immune system allowing latent virus to manifest. By example, the hallmark of herpes is latent virus expressed with the introduction of stress upon the host. The level of stress experienced by the subject in connection with the loss of his dog could have taxed the immune system allowing COVID-19 to persist in the active form long after the body should have cleared it. There have been a number of reported cases of Long COVID where patients experienced relief after receiving the vaccine. In this instance, it is possible stimulating the immune system with the vaccine helped to decrease symptoms of fatigue without ridding the body of the virus. Post Exertion Malaise (PEM) is a key symptom of Long COVID and something the subject struggled with throughout the course of his disease. The high D-Dimer indicates that the subject may have been suffering from a clotting effect localized to the scrotum as evidenced by the visible redness. Such clotting would likely impede circulation to the penis resulting in erectile dysfunction. The subject’s use of Tollovid may have helped to reduce the inflammation of the scrotum and helped stop the replication of the virus in that area as evidenced by the reduction in redness and restoration of libido within 48 hours of administration. The systemic reduction of symptoms throughout the body suggests that inhibiting 3CL protease limited the replication of the virus allowing the immune system additional time to build a more robust response better able to control and eradicate the virus. Tollovid clearly had an effect on viral persistence in a Long COVID patient and further study is warranted in the treatment of erectile dysfunction caused by a COVID-19 infection.